Print

AVEG 021

A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic in HIV-1 Seronegative Human Subjects

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) January 04, 1995
P3C541b Lipopeptide Gag B
P3C541b Lipopeptide Protein
USA 30
NCT00000845
https://clinicaltrials.gov/show/NCT00000845